In studies by Yang et al. found that an LM-based vaccine could stimulate CD8+ T cells from tumor infiltrating lymphocytes (TILs) and suppress the recruitment and differentiation of Tregs in the tumor microenvironment (Yang et al., 2014). This evidence concerns the gene CD8A and neoplasm.